MCID: CST007
MIFTS: 30

Castration-Resistant Prostate Carcinoma

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Castration-Resistant Prostate Carcinoma

MalaCards integrated aliases for Castration-Resistant Prostate Carcinoma:

Name: Castration-Resistant Prostate Carcinoma 11 14
Prostatic Neoplasms, Castration-Resistant 43

Classifications:



External Ids:

Disease Ontology 11 DOID:0080909
MeSH 43 D064129
NCIt 49 C130234

Summaries for Castration-Resistant Prostate Carcinoma

Disease Ontology: 11 A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.

MalaCards based summary: Castration-Resistant Prostate Carcinoma, also known as prostatic neoplasms, castration-resistant, is related to prostate cancer and prostate adenoid cystic carcinoma. An important gene associated with Castration-Resistant Prostate Carcinoma is HAGLR (HOXD Antisense Growth-Associated Long Non-Coding RNA), and among its related pathways/superpathways are Coregulation of Androgen receptor activity and Regulation of Androgen receptor activity. The drugs Prednisone and Antineoplastic Agents, Hormonal have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and bone.

Related Diseases for Castration-Resistant Prostate Carcinoma

Graphical network of the top 20 diseases related to Castration-Resistant Prostate Carcinoma:



Diseases related to Castration-Resistant Prostate Carcinoma

Symptoms & Phenotypes for Castration-Resistant Prostate Carcinoma

Drugs & Therapeutics for Castration-Resistant Prostate Carcinoma

Drugs for Castration-Resistant Prostate Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2 Antineoplastic Agents, Hormonal Phase 4
3 Hormones Phase 4
4 Hormone Antagonists Phase 4
5 glucocorticoids Phase 4
6 Anti-Inflammatory Agents Phase 4
7 Cytochrome P-450 Enzyme Inhibitors Phase 4
8 Androgens Phase 4
9
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181
10
Goserelin Approved Phase 3 65807-02-5 5311128 47725
11
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
12
Carbamide peroxide Approved Phase 2, Phase 3 124-43-6
13
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 2, Phase 3 62-33-9, 60-00-4 6049
14
Pentetic acid Approved Phase 2, Phase 3 67-43-6
15
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
16
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
17
Lysine Approved, Nutraceutical Phase 2, Phase 3 56-87-1 5962
18
Choline Approved, Nutraceutical Phase 2, Phase 3 62-49-7 305
19 Calcium, Dietary Phase 2, Phase 3
20 Anticoagulants Phase 2, Phase 3
21 Chelating Agents Phase 2, Phase 3
22 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
23 Immunoglobulins Phase 3
24 Antibodies Phase 3
25 Taxane Phase 3 108169
26 Antimetabolites Phase 2, Phase 3
27
Abiraterone Acetate Phase 2, Phase 3 154229-18-2 9821849
28 Gastrointestinal Agents Phase 2, Phase 3
29 Hypolipidemic Agents Phase 2, Phase 3
30 Lipid Regulating Agents Phase 2, Phase 3
31 Nootropic Agents Phase 2, Phase 3
32
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
33
Durvalumab Approved, Investigational Phase 2 1428935-60-7
34
Tremelimumab Approved, Investigational Phase 2 745013-59-6
35
Nivolumab Approved Phase 2 946414-94-4
36
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
37
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
38
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
39
Esomeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6, 119141-88-7 9568614 4594
40
Altretamine Approved Phase 2 645-05-6 2123
41
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
42
Olaparib Approved Phase 2 763113-22-0 23725625
43
Iron Approved Phase 2 7439-89-6 29936
44
Ipilimumab Approved Phase 2 477202-00-9
45
Avelumab Approved, Investigational Phase 1, Phase 2 1537032-82-8
46
Testosterone Approved, Investigational Phase 2 58-22-0 5408 6013
47
Methyltestosterone Approved Phase 2 58-18-4 6010
48
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0 21873174 65157
49
Testosterone enanthate Approved Phase 2 315-37-7 9416
50
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE) Recruiting NCT03927391 Phase 4 Enzalutamide
2 Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer Recruiting NCT03016741 Phase 4 Prednisone;Abiraterone Acetate;Enzalutamide
3 CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer Recruiting NCT04455750 Phase 3 Enzalutamide;Rucaparib camsylate;Placebo;Leuprolide Acetate;Goserelin Acetate;Degarelix
4 A Phase 2/3, Randomized, Open-label, Study of MGC018 Versus Androgen Receptor Axis-targeted Therapy (Abiraterone or Enzalutamide) in Participants With Metastatic Castration-resistant Prostate Cancer Recruiting NCT05551117 Phase 2, Phase 3 ARAT
5 VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent Recruiting NCT04844749 Phase 3 VERU-111;Enzalutamide, Abiraterone
6 Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence Active, not recruiting NCT03822845 Phase 2, Phase 3 Ga-68 PSMA-HBED-CC PET
7 A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen Active, not recruiting NCT03016312 Phase 3 Atezolizumab;Enzalutamide
8 68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients Active, not recruiting NCT03388346 Phase 2, Phase 3 Ga-68 PSMA-HBED-CC PET
9 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence Active, not recruiting NCT03389451 Phase 2, Phase 3 Ga-68 PSMA-HBED-CC PET
10 A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer Active, not recruiting NCT03748641 Phase 3 Niraparib;Abiraterone Acetate;Prednisone;Placebo;New Formulation of Niraparib and Abiraterone Acetate (AA)
11 A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer Terminated NCT02057666 Phase 3 Tasquinimod;Placebo
12 F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide Terminated NCT01981707 Phase 2, Phase 3
13 Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer Unknown status NCT04159896 Phase 2 Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
14 Phase II Open-label Study to Evaluate the Efficacy and Safety of Radium in Combination With External Beam Radiotherapy (EBRT) vs. EBRT Alone in the Treatment of Castration Resistant Prostate Carcinoma With Limited Bone Metastases Unknown status NCT02484339 Phase 2 Radium-223 dichloride
15 A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer Unknown status NCT02254785 Phase 2 cabazitaxel;Abiraterone;Enzalutamide 160mg daily (oral)
16 Docetaxel and Carboplatin for Patients With Metastatic, Castration Resistant Prostate Cancer and Inactivated Genes in BRCA 1/2 Pathway Completed NCT02598895 Phase 2 Carboplatin;Docetaxel
17 Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC) Completed NCT01881867 Phase 2
18 A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC) Completed NCT03204812 Phase 2
19 A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01576172 Phase 2 Abiraterone Acetate;Prednisone;Veliparib
20 An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01505868 Phase 1, Phase 2 Cabazitaxel;Carboplatin
21 A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide Completed NCT04157088 Phase 2 Darolutamide(Nubeqa, BAY1841788);Enzalutamide
22 A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow Recruiting NCT04754425 Phase 2 Erdafitinib
23 Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy Recruiting NCT05113537 Phase 1, Phase 2 Abemaciclib;Lutetium Lu 177-PSMA-617
24 A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response Recruiting NCT04550494 Phase 2 Talazoparib
25 A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) Recruiting NCT03317392 Phase 1, Phase 2 Olaparib
26 68Ga-PSMA-11 PET in Patients With Prostate Cancer Recruiting NCT04777071 Phase 2 Gallium Ga 68 Gozetotide
27 A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate Cancer Recruiting NCT04716725 Phase 2 68Ga-PSMA-11
28 A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Recruiting NCT04071236 Phase 1, Phase 2 Avelumab;Peposertib
29 Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers Recruiting NCT04592237 Phase 2 Cabazitaxel;Carboplatin;Niraparib
30 A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer Recruiting NCT04471974 Phase 2 BET Bromodomain Inhibitor ZEN-3694;Enzalutamide
31 Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer Recruiting NCT03999515 Phase 2 Abiraterone Acetate;Enzalutamide;Erdafitinib
32 AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease Recruiting NCT05168618 Phase 2 Cabozantinib S-malate
33 Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial Recruiting NCT03419234 Phase 2 Abiraterone Acetate;Antiandrogen Therapy;Cabazitaxel;Prednisone
34 A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging Recruiting NCT03503344 Phase 2 Apalutamide
35 Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature Recruiting NCT04951492 Phase 2 Olaparib
36 PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Recruiting NCT03442556 Phase 2 Carboplatin;Docetaxel;Rucaparib Camsylate;Rucaparib
37 A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer Recruiting NCT04381832 Phase 1, Phase 2 Etrumadenant;Zimberelimab;Quemliclustat;Enzalutamide;Docetaxel;SG
38 Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate Cancer Recruiting NCT04717154 Phase 2
39 A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Recruiting NCT04104776 Phase 1, Phase 2 CPI-0209
40 A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer Recruiting NCT05169684 Phase 2 Docetaxel
41 A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer Recruiting NCT04868604 Phase 1, Phase 2 64Cu-SAR-bisPSMA;67Cu-SAR-bisPSMA
42 FASN Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Salvaging Taxane Failure Recruiting NCT04337580 Phase 2 Omeprazole 80 mg twice daily
43 A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting NCT04918810 Phase 2 Docetaxel intermittent;Docetaxel standard of care
44 Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Recruiting NCT05252390 Phase 1, Phase 2 NUV-868;Olaparib;Enzalutamide
45 A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer Active, not recruiting NCT04033432 Phase 2
46 Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer Active, not recruiting NCT03344211 Phase 2 Enzalutamide
47 A Single Arm Phase II Study of Bone-Targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer With Skeletal Metastases Active, not recruiting NCT04616547 Phase 2
48 A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer Active, not recruiting NCT02703623 Phase 2 Abiraterone Acetate;Apalutamide;Cabazitaxel;Carboplatin;Prednisone
49 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment Active, not recruiting NCT02099864 Phase 2 Enzalutamide
50 Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC Active, not recruiting NCT02312557 Phase 2 Enzalutamide

Search NIH Clinical Center for Castration-Resistant Prostate Carcinoma

Cochrane evidence based reviews: prostatic neoplasms, castration-resistant

Genetic Tests for Castration-Resistant Prostate Carcinoma

Anatomical Context for Castration-Resistant Prostate Carcinoma

Organs/tissues related to Castration-Resistant Prostate Carcinoma:

MalaCards : Prostate, Testes, Bone, Salivary Gland, T Cells, Bone Marrow, Endothelial

Publications for Castration-Resistant Prostate Carcinoma

Articles related to Castration-Resistant Prostate Carcinoma:

(show all 48)
# Title Authors PMID Year
1
Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity. 62
36006609 2022
2
Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective. 62
36153234 2022
3
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. 62
35177427 2022
4
177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. 62
36125377 2022
5
High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1-actin Complex as a New Potential Target for Therapy. 62
35456960 2022
6
Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report. 62
35187388 2021
7
Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. 62
31602963 2021
8
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. 62
34205686 2021
9
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. 62
34069003 2021
10
Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. 62
33560718 2021
11
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma. 62
34385780 2021
12
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]. 62
33621992 2021
13
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. 62
33754047 2021
14
Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House. 62
34845436 2021
15
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. 62
33067297 2020
16
Extensive colonic pneumatosis. Conservative or Surgical approach? 62
32496113 2020
17
Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. 62
32449086 2020
18
Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival? 62
32862614 2020
19
Asymptomatic Metastasis to Thyroid Cartilage Detected by 18F-Choline and 64Cu-PSMA PET/CT as a Single Site of Disease Relapse in a Patient With Castration-Resistant Prostate Carcinoma. 62
31652161 2020
20
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. 62
31101746 2020
21
Determination of split renal function by PSMA imaging: comparison of 68Ga-PSMA-11 PET with 99mTc-MAG3 scintigraphy. 62
33224621 2020
22
Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma. 62
31688499 2019
23
Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results. 62
31781962 2019
24
Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma. 62
31229922 2019
25
[The modern treatment of metastatic castration-resistant prostate cancer]. 62
30889620 2019
26
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma. 62
30204613 2019
27
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma. 62
29688951 2018
28
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. 62
29485430 2018
29
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. 62
29268139 2018
30
Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases. 62
28645684 2018
31
Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression. 62
29113300 2017
32
[Mechanisms for castration-resistance of prostate carcinoma]. 62
29093256 2017
33
[Molecular basis for prostate carcinogenesis]. 62
28626107 2017
34
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases. 62
28085175 2017
35
Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. 62
27749411 2016
36
[Strategies for First-Line Treatment of mCRPC]. 62
27680191 2016
37
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. 62
26100652 2015
38
Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization. 62
26093146 2015
39
(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. 62
25070686 2015
40
Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma. 62
24995642 2014
41
Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. 62
24202668 2014
42
Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma. 62
23832735 2013
43
Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma. 62
23190319 2012
44
[New drug treatment possibilities in castration resistant prostate carcinoma]. 62
22945814 2012
45
Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. 62
23023354 2012
46
NF-κB signaling in prostate cancer: a promising therapeutic target? 62
22085980 2012
47
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. 62
21106727 2011
48
¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. 62
20862471 2011

Variations for Castration-Resistant Prostate Carcinoma

Expression for Castration-Resistant Prostate Carcinoma

Search GEO for disease gene expression data for Castration-Resistant Prostate Carcinoma.

Pathways for Castration-Resistant Prostate Carcinoma

Pathways related to Castration-Resistant Prostate Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.94 KLK3 AR
2 10.65 KLK3 AR
3 10.19 KLK3 AR

GO Terms for Castration-Resistant Prostate Carcinoma

Biological processes related to Castration-Resistant Prostate Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of systemic arterial blood pressure GO:0003073 8.92 KLK3 AR

Sources for Castration-Resistant Prostate Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....